MedTrace Logo

Efficacy of Contrast Enhanced Voiding Urosonography for Urodynamic Studies

NCT04738539 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2021-04-28

No results posted yet for this study

Summary

The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic studies.

Conditions

  • Myelomeningocele
  • Neurogenic Bladder
  • Tethered Cord Syndrome
  • Bladder, Neurogenic
  • Urologic Diseases
  • Neurologic Dysfunction

Interventions

DRUG

Contrast Enhanced Voiding Urosonography with Urodynamic Testing

We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.

DIAGNOSTIC_TEST

Urodynamic Testing

We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Nora G Kern, MD · University of Virginia

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-02
Primary Completion
2022-03-02
Completion
2022-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04738539 on ClinicalTrials.gov